Brain health: time matters in multiple sclerosis

We present international consensus recommendations for improving diagnosis, management and treatment access in multiple sclerosis (MS). Our vision is that these will be used widely among those committed to creating a better future for people with MS and their families. Structured discussions and lit...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	Multiple sclerosis and related disorders Ročník 9; s. S5 - S48
Hlavní autoři:	Giovannoni, Gavin, Butzkueven, Helmut, Dhib-Jalbut, Suhayl, Hobart, Jeremy, Kobelt, Gisela, Pepper, George, Sormani, Maria Pia, Thalheim, Christoph, Traboulsee, Anthony, Vollmer, Timothy
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	Netherlands Elsevier B.V 01.09.2016
Témata:	Brain - physiopathology Consensus statement Disease activity Disease-modifying therapy (DMT) Humans Magnetic resonance imaging (MRI) Multiple sclerosis Multiple Sclerosis - diagnosis Multiple Sclerosis - economics Multiple Sclerosis - physiopathology Multiple Sclerosis - therapy Neurology Time Factors Treatment strategy RRMS Treatment strategy FDA RCT Multiple sclerosis NRSPMS PPMS MRI CNS ABN Consensus statement AUD NEDA EMA US EDSS RWE Disease-modifying therapy (DMT) Disease activity SPMS MS Magnetic resonance imaging (MRI) GP DMT CIS € AAN HTA QALY EUReMS RIS MoA RSPMS health technology assessment US dollars Australian dollars general practitoner (family or primary care physician) disease activity secondary progressive multiple sclerosis disease-modifying therapy (DMT) relapsing–remitting multiple sclerosis Food and Drug Administration (the US regulatory authority) American Academy of Neurology central nervous system consensus statement primary progressive multiple sclerosis relapsing secondary progressive multiple sclerosis disease-modifying therapy Association of British Neurologists magnetic resonance imaging real-world evidence no evidence of disease activity RICT radiologically isolated syndrome non-relapsing secondary progressive multiple sclerosis euros treatment strategy multiple sclerosis mechanism of action Kurtzke Expanded Disability Status Scale quality-adjusted life year randomized controlled trial European Register for Multiple Sclerosis magnetic resonance imaging (MRI) European Medicines Agency (the European regulatory authority) clinically isolated syndrome
ISSN:	2211-0348, 2211-0356
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Buďte první, kdo okomentuje tento záznam!